<DOC>
	<DOCNO>NCT01155700</DOCNO>
	<brief_summary>The primary purpose study examine whether geometric mean serum free IgE level 24 week treatment period Japanese pediatric patient ( 6 15 year age ) reach 25 ng/mL ( target level ) . The investigator also assess well PK/PD data Japanese child fit global PK-PD modeling build Caucasian adult child , ass efficacy safety data Japanese pediatric patient fulfill Japanese health authority requirement approval . Data obtain study intend used support registration pediatric indication omalizumab Japan .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics , Efficacy Safety Omalizumab Japanese Children ( 6 - 15 Years )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Body weight serum total IgE level within dose table range ; body weight 20 150 kg serum total IgE level 30 1300 IU/mL Receiving asthma longterm control medication high dose ICS ( &gt; 200 µg/day FP equivalent ) two controller medication LTRA , theophylline , sodium cromoglycate , LABA , OCSs 12 week prior runin period . These medication keep stable 4 week prior runin period runin period ( except management asthma attacks/exacerbations ) Having 2 asthma exacerbation require treatment double maintenance ICS dose least 3 day and/or systemic ( oral IV ) corticosteroid past ; one exacerbation must occur previous 12 month , document medical record Demonstrating inadequately control asthma symptom last 14 day runin period base patient diary meet following : Asthma symptom every day ; Nighttime symptoms ≥2 last 14 day ( miss data treat day symptom ) ; Limitation daily activity ≥2 last 14 day ( miss data treat day limitation ) With history food drug relate severe anaphylactoid anaphylactic reaction ( ) With positive skin reaction study drug runin period With known hypersensitivity ingredient , include excipients ( sucrose , histidine , polysorbate 20 ) study drug drug relate omalizumab ( e.g. , monoclonal antibody , polyclonal gamma globulin ) With platelet level ≤ 100,000/µL ( 100 x 109/L ) runin period Who take intramuscular deposteroids within 4 week runin period Who take systemic ( oral IV ) corticosteroid reason asthma within 4 week runin period ( patient chronic OCSs use asthma allow ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>omalizumab</keyword>
	<keyword>allergic asthma</keyword>
	<keyword>pediatric patient</keyword>
</DOC>